SLC5A1 and heart failure: In an efficient and elaborate study done by Lee et al, comprising 52,607 patients from 10 trials, it was shown that in patients with heart failure, the SGLT-2 inhibitors with low selectivity towards SGLT-1 and SGLT-2 had a greater impact on reducing the risk of hospitalization for heart failure (HHF) compared to agents with higher selectivity [5,9].